Evidence map›Paper›PMID 25697643›Full record

ArticleEpidemiology and infection2015

Preferential carriage of class 2 integrons in Acinetobacter baumannii CC113 and novel singletons.

M S Ramírez, S Montaña, M Cassini, D Centrón

Open access · bronzeAbstract read
In one paragraph

Article in Epidemiology and infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Genomic Analysis of Carbapenem-ResistantFrontiers in microbiology · 2020
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

M S RamírezInstituto de Microbiología y Parasitología Médica (IMPaM, UBA-CONICET),Facultad de Medicina,Universidad de Buenos Aires,Argentina.
S MontañaInstituto de Microbiología y Parasitología Médica (IMPaM, UBA-CONICET),Facultad de Medicina,Universidad de Buenos Aires,Argentina.
M CassiniGrupo GEMA,Departamento de Ciencias Básicas,Universidad Nacional de Luján,Luján,Buenos Aires,Argentina & Laboratorio de Biología del Comportamiento,IBYME,Ciudad Autónoma de Buenos Aires,Argentina.
D CentrónInstituto de Microbiología y Parasitología Médica (IMPaM, UBA-CONICET),Facultad de Medicina,Universidad de Buenos Aires,Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARCalifornia State University, Fullerton · USNational University of Luján · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our understanding of the distribution of integrons associated with multidrug resistance in Acinetobacter baumannii isolates around the world remains incomplete. The association between the class 1 and 2 integron A. baumannii-positive isolates (n = 60), recovered since 1982 from 11 Argentinean hospitals, and the circulating lineages, was investigated. While class 2 integrons were highly significantly associated with clonal lineage CC113B/CC79P (P = 0·009) and novel singletons (P = 0·001), class 1 integrons were found not to be associated with CC109B/CC1P or other lineages. The study reveals a differential distribution of class 2 integrons in lineages, and suggests that the prevalence of intI2 in Argentina is related to the emergence of novel singletons in recent years and to the abundance of CC113B/CC79P, which has been the local dominant lineage for several decades.

Indexed as

IntegronsAcinetobacter baumanniiAcinetobacter InfectionsArgentinaDrug Resistance, Multiple, BacterialGenotypeHumansMolecular EpidemiologyAcinetobacterintegronlineages

Identifiers

PMID25697643
PMCPMC9151031
OpenAlexW2171177675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.